Research graph
References from Phase I study of dose dense induction and consolidation with gemtuzumab ozogamicin and high dose cytarabine in older adults with AML. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics
10.3322/caac.20107 · 2011 · External reference
Management of acute myeloid leukemia in elderly patients
10.1200/jco.1999.17.11.3569 · 1999 · External reference
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
10.1182/blood-2002-03-0772 · 2002 · External reference
Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study
10.1182/blood.v89.9.3323 · 1997 · External reference
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group
1999 · External reference
10.1038/sj.leu.2401445
10.1038/sj.leu.2401445 · 1999 · External reference
Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group
10.3109/10428199809092687 · 1998 · External reference
High-dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years
10.1002/cncr.26290 · 2012 · External reference
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
10.1200/jco.2001.19.13.3244 · 2001 · External reference
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902
10.1016/j.leukres.2010.07.017 · 2011 · External reference
Is there a role for postremission therapy in older adults with acute myelogenous leukemia (AML)?
10.1038/sj.leu.2403827 · 2005 · External reference
Unresolved reference
External reference
Design and analysis of phase I clinical trials
10.2307/2531693 · 1989 · External reference
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
10.1200/jco.2003.04.036 · 2003 · External reference
Preliminary report of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg) given in combination with cytarabine and daunorubicin in patients with acute myeloid leukemia
2001 · External reference
Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation
10.1182/blood-2003-01-0255 · 2003 · External reference
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence
10.1002/cncr.21326 · 2005 · External reference
High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group
10.1038/sj.leu.2404434 · 2007 · External reference
Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas
10.1080/1042819042000219485 · 2004 · External reference
10.1111/j.1365-2141.2010.08095.x
10.1111/j.1365-2141.2010.08095.x · 2010 · External reference
10.1038/sj.leu.2403901
10.1038/sj.leu.2403901 · 2005 · External reference
Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older
10.1016/j.leukres.2004.04.011 · 2005 · External reference
Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia
10.1200/jco.2007.15.9764 · 2008 · External reference
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia
10.1016/s0145-2126(03)00022-5 · 2003 · External reference
Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group
10.1111/j.1365-2141.2009.07917.x · 2010 · External reference
Identification of patients with acute myeloblastic leukaemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial
10.1200/jco.2010.31.4310 · 2011 · External reference
10.1093/annonc/mdr346
10.1093/annonc/mdr346 · External reference
10.1182/blood.v114.22.790.790
10.1182/blood.v114.22.790.790 · 2009 · External reference
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside
10.1182/blood.v99.12.4343 · 2002 · External reference
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years
10.1016/j.leukres.2008.05.011 · 2008 · External reference
Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older
10.1111/j.1600-0609.2007.00946.x · 2007 · External reference
A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia
10.1182/blood-2003-05-1620 · 2003 · External reference
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes
10.1002/cncr.11239 · 2003 · External reference
Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups
2004 · External reference
10.1111/j.1365-2141.2007.06646.x
10.1111/j.1365-2141.2007.06646.x · 2007 · External reference
Unresolved reference
2011 · External reference
Nucleoside analogues: mechanisms of drug resistance and reversal strategies
10.1038/sj.leu.2402114 · 2001 · External reference
Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells
10.1097/00001813-199102000-00007 · 1991 · External reference
Comparison of the induction of apoptosis in human leukemic cell lines by 2',2'-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside
10.1016/0145-2126(95)00067-4 · 1995 · External reference
Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma
10.1200/jco.2002.08.166 · 2002 · External reference
Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia
10.1080/10428190802210700 · 2008 · External reference
Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia
10.1200/jco.2009.22.2547 · 2009 · External reference
